Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
Am J Med Genet C Semin Med Genet ; 184(3): 618-630, 2020 09.
Article in English | MEDLINE | ID: mdl-32866347

ABSTRACT

The spectrum of peroxisomal disorders is wide and comprises individuals that die in the first year of life, as well as people with sensorineural hearing loss, retinal dystrophy and amelogenesis imperfecta. In this article, we describe three patients; two diagnosed with Heimler syndrome and a third one with a mild-intermediate phenotype. We arrived at these diagnoses by conducting complete ophthalmic (National Eye Institute), auditory (National Institute of Deafness and Other Communication Disorders), and dental (National Institute of Dental and Craniofacial Research) evaluations, as well as laboratory and genetic testing. Retinal degeneration with macular cystic changes, amelogenesis imperfecta, and sensorineural hearing loss were features shared by the three patients. Patients A and C had pathogenic variants in PEX1 and Patient B, in PEX6. Besides analyzing these cases, we review the literature regarding mild peroxisomal disorders, their pathophysiology, genetics, differential diagnosis, diagnostic methods, and management. We suggest that peroxisomal disorders are considered in every child with sensorineural hearing loss and retinal degeneration. These patients should have a dental evaluation to rule out amelogenesis imperfecta as well as audiologic examination and laboratory testing including peroxisomal biomarkers and genetic testing. Appropriate diagnosis can lead to better genetic counseling and management of the associated comorbidities.


Subject(s)
ATPases Associated with Diverse Cellular Activities/genetics , Amelogenesis Imperfecta/genetics , Hearing Loss, Sensorineural/genetics , Membrane Proteins/genetics , Nails, Malformed/genetics , Peroxisomal Disorders/genetics , Adolescent , Adult , Amelogenesis Imperfecta/complications , Amelogenesis Imperfecta/diagnosis , Amelogenesis Imperfecta/pathology , Child , Female , Genetic Counseling , Hearing Loss, Sensorineural/complications , Hearing Loss, Sensorineural/diagnosis , Hearing Loss, Sensorineural/pathology , Humans , Male , Nails, Malformed/complications , Nails, Malformed/diagnosis , Nails, Malformed/pathology , Pedigree , Peroxisomal Disorders/complications , Peroxisomal Disorders/diagnosis , Peroxisomal Disorders/pathology , Phenotype , Retinal Degeneration/diagnosis , Retinal Degeneration/genetics , Retinal Degeneration/pathology , Young Adult
2.
Adv Exp Med Biol ; 1185: 317-321, 2019.
Article in English | MEDLINE | ID: mdl-31884631

ABSTRACT

Peroxisomal disorders are a group of inherited metabolic diseases, which can be incompatible with life in the postnatal period or allow survival into adulthood. Retinopathy is a recurrent feature in both the severely and mildly affected patients, which can be accompanied with other ophthalmological pathologies. Thanks to next-generation sequencing, patients originally identified with other inherited blinding diseases were reclassified as suffering from peroxisomal disorders. In addition, new peroxisomal gene defects or disease presentations exhibiting retinal degeneration were recently identified. The pathogenic mechanisms underlying retinopathy in peroxisomal disorders remain unresolved.


Subject(s)
Peroxisomal Disorders/complications , Retinal Degeneration/complications , Humans , Peroxisomal Disorders/genetics , Retinal Degeneration/genetics
3.
Rev. bras. oftalmol ; 78(6): 403-405, nov.-dez. 2019.
Article in English | LILACS | ID: biblio-1057919

ABSTRACT

Abstract X-linked adrenoleukodystrophy (X-ALD) represents a group of diseases characterized by the accumulation of very long chain fattyacids (VLCFAs) in the tissues. Its clinical manifestations are usually manifold. Visual changes may be present, but they often appear later in the disease. We describe here the case of a 9-year-old boy with X-ALD, whose first symptom was visual loss, which began at 8 years of age. His ophthalmologic evaluation revealed no alterations. Shortly thereafter, he suffered a head injury. The magnetic resonance imaging of brain revealed findings that led to the suspicion of X-ALD. The plasma VLCFA dosage confirmed this diagnosis. This report aims toshow that in cases of visual loss with a normal ophthalmic examination, a high index of suspicion should be given for conditions suchas X-ALD, since it affects the cortical routes related to vision. Fundoscopy findings appear late in X-ALD.


Resumo A adrenoleucodistrofia ligada ao X (X-ALD) representa um grupo de doenças caracterizadas pelo acúmulo de ácidos graxos de cadeia muito longa (VLCFAs) nos tecidos. Suas manifestações clínicas costumam ser múltiplas. Alterações visuais podem estar presentes, contudo costumam surgir mais tardiamente na doença. Descrevemos aqui o caso de um menino de 9 anos com X-ALD, cujo primeiro sintoma foi perda visual, iniciada aos 8 anos de idade. A sua avaliação oftalmológica não revelou alterações. Pouco tempo depois, ele sofreu um traumatismo craniano. A imagem de ressonância magnética de encéfalo revelou achados que levaram a suspeita de X-ALD. A dosagem dos VLCFAs no plasma confirmou este diagnóstico. Este relato tem como objetivo mostrar que em casos de perda visual com um exame oftalmológico normal, deve-se ter um alto índice de suspeita para condições como a X-ALD, pois a mesma afeta as vias corticais relacionadas à visão. Nessa doença, os achados da fundoscopia aparecem mais tardiamente.


Subject(s)
Humans , Male , Child , Vision Disorders/etiology , Adrenoleukodystrophy/complications , Magnetic Resonance Imaging , Peroxisomal Disorders/complications , Peroxisomal Disorders/diagnosis , Adrenoleukodystrophy/diagnosis , Blindness, Cortical/etiology , Fatty Acids/blood
4.
Ophthalmic Genet ; 39(3): 377-379, 2018 06.
Article in English | MEDLINE | ID: mdl-29377746

ABSTRACT

Peroxisomal biogenesis disorders are caused by disruption of long chain fatty acid metabolism due to mutations in PEX genes. Individuals with these disorders often have vision loss due to optic atrophy and pigmentary retinopathy. We report an unusual retinal manifestation of peroxisomal biogenesis disorder.


Subject(s)
Peroxisomal Disorders/pathology , Peroxisomal Disorders/surgery , Retinal Diseases/pathology , Retinal Diseases/surgery , Child, Preschool , Female , Humans , Peroxisomal Disorders/complications , Prognosis , Retinal Diseases/complications
5.
Anaesthesist ; 66(12): 944-947, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29119207

ABSTRACT

We present the case of an 8­year-old female child with suspected peroxisomal disorder requiring general anesthesia for adenotomy, paracentesis and brainstem-evoked response audiometry. Peroxisomes are small intracellular organelles that catalyse key metabolic reactions. Peroxisomal disorders are a heterogeneous group of rare genetic diseases. Anesthesia can be challenging as adrenal insufficiency, mental retardation, muscle weakness, risk of pulmonary aspiration, airway complications, seizure disorders and altered pharmacokinetics and pharmacodynamics can occur in these patients but guidelines for anesthesia do not exist due to the heterogeneity and rarity of these diseases and case reports are rare. Anesthesia was induced by sevoflurane via a face mask, followed by remifentanil and rocuronium for oral intubation after intravenous access was obtained. Anesthesia was maintained with sevoflurane and remifentanil. Dexamethasone was given for prophylaxis of postoperative nausea and vomiting as well as perioperative adrenal crises. Piritramide was given for postoperative analgesia. With this approach anesthesia was uneventful. The trachea was extubated with the patient awake and she was taken to the recovery room in a stable condition. The classification and breadth of clinical manifestations of peroxisomal disorders is complex and briefly summarized. Anesthesiologists should consider characteristics of their particular patient's form of peroxisomal disorder, as this may greatly influence procedural planning.


Subject(s)
Anesthesia, General/methods , Peroxisomal Disorders/complications , Airway Extubation , Analgesics, Opioid/therapeutic use , Androstanols , Anesthetics, Inhalation , Anesthetics, Intravenous , Antiemetics/therapeutic use , Child , Dexamethasone/therapeutic use , Female , Humans , Methyl Ethers , Neuromuscular Nondepolarizing Agents , Pain, Postoperative/drug therapy , Piperidines , Pirinitramide/therapeutic use , Postoperative Nausea and Vomiting/prevention & control , Remifentanil , Rocuronium , Sevoflurane
6.
J Neurol Sci ; 375: 424-429, 2017 Apr 15.
Article in English | MEDLINE | ID: mdl-28320181

ABSTRACT

Peroxisome biogenesis factor 10 (PEX10) is involved in the import of peroxisomal matrix proteins, and the mutation of this gene causes 3 subtypes of peroxisome biogenesis disorders, namely Zellweger syndrome (severe), neonatal adrenoleukodystrophy (moderate) and an ataxic form (mild). Here, we report 3 siblings of the ataxic form with cerebellar ataxia, mild mental retardation, and 3 additional characteristic features: mydriasis, hyperreflexia and involuntary head movement. All 3 siblings are compound heterozygous for a previously reported mutation, c.2T>C (p.M1T), and a novel mutation, c.920G>A, causing a missense change (p.C307Y) located in the RING finger domain of PEX10. The present cases suggest that these PEX10 mutations involve not only cerebellar but also more multiple nervous systems including pupillary autonomic, pyramidal and extrapyramidal systems.


Subject(s)
Cerebellar Ataxia/genetics , Family Health , Mutation/genetics , Peroxisomal Disorders/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Adult , Cerebellar Ataxia/complications , Cerebellar Ataxia/diagnostic imaging , DNA Mutational Analysis , Female , Humans , Magnetic Resonance Imaging , Male , Peroxins , Peroxisomal Disorders/complications , Peroxisomal Disorders/diagnostic imaging , Phenotype
7.
Neuropediatrics ; 47(3): 179-81, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26947510

ABSTRACT

Peroxisome biogenesis disorders (PBD) are a heterogeneous group of disorders due to PEX genes mutations, with a broad clinical spectrum comprising severe neonatal disease to mild presentation. Recently, Berendse et al reported an improvement of peroxisomal functions with l-arginine supplementation in fibroblasts with specific mutations of PEX1, PEX6, and PEX12. We report the first treatment by l-arginine in a patient homozygous for the specific PEX12 mutation shown to be l-arginine responsive in fibroblasts. We described the effect of l-arginine on biochemical (decrease of some plasma peroxisomal parameters) and neurophysiological (improvement of deafness) parameters. Some subjective clinical effects have also been observed (no more sialorrhea, behavior improvement). More studies are needed to assess the efficacy of l-arginine in some PBD patients with specific mutations.


Subject(s)
Arginine/therapeutic use , Membrane Proteins/genetics , Peroxisomal Disorders/drug therapy , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Child , Child, Preschool , Deafness/etiology , Developmental Disabilities/etiology , Fatty Acids/blood , Female , Humans , Infant , Membrane Proteins/deficiency , Muscle Hypotonia/etiology , Peroxisomal Disorders/blood , Peroxisomal Disorders/complications , Peroxisomal Disorders/genetics , Phytanic Acid/blood , Pipecolic Acids/blood , Sialorrhea/etiology
9.
Semin Ophthalmol ; 29(5-6): 319-28, 2014.
Article in English | MEDLINE | ID: mdl-25325857

ABSTRACT

Inherited retinal degeneration (IRD) may occur in isolation or as part of a multi-systemic condition. Ocular manifestations may be the presenting symptom of a syndromic disease and can include retinitis pigmentosa, cone-rod dystrophy, or maculopathy. Alternatively, patients affected with syndromic disease may already have other systemic manifestations at the time retinal disease is diagnosed. Some of these systemic diseases can cause significant morbidity. Here, we review several of these syndromic IRDs and their underlying genetic causes. Early recognition and referral for systemic evaluation and surveillance may lead to early intervention and an improved outcome. Obtaining a molecular diagnosis can be beneficial in securing a definitive diagnosis, especially in cases with atypical presentations. A genetic diagnosis may also be informative with regard to prognosis and potential therapies. Effective management and rehabilitation for patients with syndromic retinal dystrophy requires a comprehensive genetic-based team approach involving patients, family members, ophthalmologists, primary care physicians, and geneticists.


Subject(s)
Lysosomal Storage Diseases/complications , Mitochondrial Diseases/complications , Peroxisomal Disorders/complications , Retinal Dystrophies/complications , Cilia/pathology , Genetic Testing , Humans , Lysosomal Storage Diseases/diagnosis , Lysosomal Storage Diseases/genetics , Mitochondrial Diseases/diagnosis , Mitochondrial Diseases/genetics , Peroxisomal Disorders/diagnosis , Peroxisomal Disorders/genetics , Retinal Dystrophies/diagnosis , Retinal Dystrophies/genetics
10.
Acta pediatr. esp ; 71(1): 27-27[e4-e10], ene. 2013. tab, graf, ilus
Article in Spanish | IBECS | ID: ibc-109402

ABSTRACT

La condrodisplasia punctata rizomélica clásica (RCDP) es una rara enfermedad multisistémica autosómica recesiva, debida a una alteración del metabolismo peroxisomal que determina una deficiencia de la biosíntesis de plasmalógenos y de la alfaoxidación del ácido fitánico. Se caracteriza por la presencia desde el nacimiento de un acortamiento proximal de las extremidades, calcificaciones periarticulares, dismorfia facial, retraso del desarrollo y mortalidad precoz. Se presentan dos casos de RCDP clásica, o tipo I, con las dos formas clínicas de presentación, grave o mortal y leve o benigna, en relación con la existencia de actividad enzimática residual, y se revisan sus principales aspectos clínicos(AU)


Classic rhizomelic chondrodysplasia punctata (CRCP) is a rare multisystem disease, autosomal recessive disorder. It is due because a peroxisomal metabolism alteration that determine deficiency of the plasmalogen biosynthesis and the alpha oxidation of phytanic acid. It is characterized by proximal shortening of the limbs, punctuate calcifications of the epiphyses, facial dysmorphia, developmental delay and early lethality. We present two cases of CRCP type I with two different forms of presentation, one severe and another one mild or bening, in relation with the residual enzyme activity and we revise the main clinical aspects(AU)


Subject(s)
Humans , Male , Female , Infant, Newborn , Chondrodysplasia Punctata/complications , Chondrodysplasia Punctata/diagnosis , Chondrodysplasia Punctata/therapy , Chondrodysplasia Punctata, Rhizomelic/complications , Chondrodysplasia Punctata, Rhizomelic/diagnosis , Chondrodysplasia Punctata/physiopathology , Chondrodysplasia Punctata , Peroxisomal Disorders/complications , Peroxisomal Disorders/diagnosis , Diagnosis, Differential , Lower Extremity/pathology , Lower Extremity , Lower Extremity Deformities, Congenital
12.
Brain Dev ; 33(9): 777-82, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21397417

ABSTRACT

Peroxisomes are organelles responsible for multiple metabolic pathways including the biosynthesis of plasmalogens and the oxidation of branched-chain as well as very-long-chain fatty acids (VLCFAs). Peroxisomal disorders (PDs) are heterogeneous groups of diseases and affect many organs with varying degrees of involvement. Even pathogenetically distinct PDs share some common symptoms. However, several PDs have uniquely characteristic clinical findings. The durations of survival in PDs are also variable. Infants with PDs are usually presented with developmental delay, visual and hearing impairment. Generalized hypotonia is present in severe cases. Epileptic seizures are also a common characteristic of patients with certain PDs. Nonetheless, the classification and evolution of epilepsy in PDs have not been elucidated in detail. Here, we review the relevant literatures and provide an overview of PDs with particular emphasis on the characteristics of seizures in infants.


Subject(s)
Peroxisomal Disorders/complications , Seizures/etiology , Humans , Infant , Peroxisomal Disorders/classification , Peroxisomal Disorders/diagnosis , Seizures/classification , Seizures/diagnosis
14.
Indian J Pediatr ; 77(10): 1151-2, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20872098

ABSTRACT

Failure to thrive is not uncommon in paediatric practice and often leads to multiple investigations to find the underlying cause. We report an infant who presented mainly with mild dysmorphism, failure to thrive and elevated alanine transferase (ALT) in early infancy. She was diagnosed to have a peroxisomal biogenesis disorder on further investigation. Peroxisomal disorders represent a spectrum of conditions with absent or abnormal function of intra-cytoplasmic organelles called peroxisomes. Clinical presentation is quite varied, depending on both the type and severity. We describe the clinical presentation of this case, followed by a brief discussion on peroxisomal disorders.


Subject(s)
Failure to Thrive/etiology , Peroxisomal Disorders/diagnosis , Female , Humans , Infant , Peroxisomal Disorders/complications
16.
J Inherit Metab Dis ; 31 Suppl 2: S453-6, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19089597

ABSTRACT

We report a 16-month-old asymptomatic male with enzyme confirmed isovaleric acidaemia (IVA; isovaleryl-CoA dehydrogenase deficiency; OMIM 243500) who, upon routine nutritional follow-up, presented evidence of peroxisomal dysfunction. The newborn screen (2 days of life) revealed elevated C(5)-carnitine (2.95 µmol/L; cutoff <0.09 µmol/L) and IVA was subsequently confirmed by metabolic profiling and in vitro enzymology. Plasma essential fatty acid (EFA) analysis, assessed to evaluate nutritional status during protein restriction and L: -carnitine supplementation, revealed elevated C(26:0) (5.0 µmol/L; normal <1.3). Subsequently, metabolic profiling and molecular genetic analysis confirmed X-linked adrenoleukodystrophy (XALD). Identification of co-inherited XALD with IVA in this currently asymptomatic patient holds significant treatment ramifications for the proband prior to the onset of neurological sequelae, and critically important counselling implications for this family.


Subject(s)
Amino Acid Metabolism, Inborn Errors/diagnosis , Fatty Acids, Essential/blood , Nutrition Assessment , Peroxisomal Disorders/diagnosis , Amino Acid Metabolism, Inborn Errors/blood , Amino Acid Metabolism, Inborn Errors/complications , Amino Acid Metabolism, Inborn Errors/genetics , Biomarkers/blood , DNA Mutational Analysis , Humans , Infant , Infant, Newborn , Isovaleryl-CoA Dehydrogenase/blood , Isovaleryl-CoA Dehydrogenase/deficiency , Isovaleryl-CoA Dehydrogenase/genetics , Male , Neonatal Screening , Peroxisomal Disorders/blood , Peroxisomal Disorders/complications , Peroxisomal Disorders/genetics , Predictive Value of Tests
17.
Pediatr Neurol ; 38(2): 137-9, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18206797

ABSTRACT

Neonatal seizures are critical conditions because they are usually related to significant illnesses that require a specific therapy. Antepartum and peripartum seizures are very rare, and represent signs of prenatal-onset neurologic dysfunction. A review of the literature revealed that the main etiologies include severe brain malformations, multiple anomalies, and metabolic encephalopathy. A high incidence of early fatality and serious neurologic sequelae were noted. To our knowledge, this is the first case report of neonatal adrenoleukodystrophy presenting with seizure at birth. These very-early-onset seizures may require unique diagnostic and therapeutic considerations, in contrast with the later onset of seizures in neonates.


Subject(s)
Peroxisomal Disorders/physiopathology , Seizures/physiopathology , Adult , Brain/pathology , Fatal Outcome , Female , Humans , Infant, Newborn , Magnetic Resonance Imaging , Peroxisomal Disorders/blood , Peroxisomal Disorders/complications , Pregnancy , Seizures/blood , Seizures/congenital
18.
Rev. esp. cardiol. Supl. (Ed. impresa) ; 7(supl.H): 20h-28h, 2007. ilus
Article in Spanish | IBECS | ID: ibc-166354

ABSTRACT

El descubrimiento del papel de los ácidos grasos libres en el desarrollo de la diabetes y sus complicaciones ha supuesto un cambio en el enfoque terapéutico de la diabetes. El exceso de ácidos grasos libres plasmáticos produce un estado de hiperinsulinismo que está íntimamente relacionado con la aparición de las alteraciones metabólicas y el desarrollo de hipertensión arterial y de complicaciones vasculares en pacientes diabéticos. Los receptores activadores de la proliferación peroxisomal (PPAR), al ser estimulados, favorecen la acción de la insulina al reducir las concentraciones de ácidos grasos libres plasmáticos, reducir la producción hepática de glucosa y aumentar la captación de ésta por parte del músculo esquelético. Las glitazonas, como agonistas de dichos receptores, aportan beneficios importantes en el tratamiento de pacientes con diabetes mellitus tipo 2 (AU)


The discovery that free fatty acids play a role in the development of diabetes and its complications has brought about a change in the therapeutic approach to the disorder. In diabetic patients, an excessively high free fatty acid plasma level results in a state of hyperinsulinemia which is closely associated with the appearance of metabolic abnormalities and the development of hypertension and cardiovascular complications. The stimulation of peroxisome proliferatoractivated receptors (PPARs) promotes the action of insulin by reducing the plasma free fatty acid level, reducing hepatic glucose production, and increasing skeletal muscle glucose uptake. Glitazones, which act as PPAR agonists, offer significant benefits in the treatment of patients with type-2 diabetes mellitus (AU)


Subject(s)
Humans , Hypertension/complications , Hyperlipidemias/complications , Hyperlipidemias/therapy , PPAR gamma/analysis , Peroxisomal Disorders/complications
19.
J Child Neurol ; 20(4): 326-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15921234

ABSTRACT

Peroxisomal disorders, an expanding group of genetic disorders in humans, can be grouped into three categories: peroxisome biogenesis disorders, single peroxisomal enzyme deficiencies, and contiguous gene syndrome. At present, 13 complementation groups of peroxisome biogenesis disorders and their responsible genes have been identified, including our newly identified group with a PEX14 defect. We describe neuronal abnormalities related to deficiencies in peroxisomes and the phenotype-genotype relationship in peroxisome biogenesis disorders. We also identified 32 Japanese patients with peroxisome biogenesis disorders, subdivided into six complementation groups. Our institution acts as the only diagnostic center for studies on peroxisomal disorders in Japan.


Subject(s)
Peroxisomal Disorders/complications , Peroxisomal Disorders/genetics , Asian People/genetics , Genetic Heterogeneity , Genotype , Humans , Mutation/genetics , PHEX Phosphate Regulating Neutral Endopeptidase , Phenotype , Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...